Max Access Solutions is our innovative, patient-centered model for delivering cancer treatment to those in need. Through the program, launched in 2017, we connect people facing cancer in countries where treatment is not locally available to high impact medicines, qualified medical professionals and essential support services.
This work is made possible through partnerships with local physicians, ministries of health, other non-governmental organizations, patient organizations, and medicine manufacturers. Our partner physicians play a vital role in receiving the medication at the local level, enrolling patients into the program and providing the individual care each patient needs.
Max Access Solutions is meant to bridge access to treatment in underserved areas, with a focus on low- and middle-income countries, until local access channels can be put in place.
- 37K+
patients provided access to medication and/or support services each year
- 83
countries where medication access and/or support services are provided
- 16
cancer medicines provided
“The access to drugs, at no cost, has not only helped me financially but also enhanced my overall wellbeing. This has enabled me to sustain my occupation as a farmer, which demands immense endurance and physical strength. As a patient facing financial constraints, the provision of such vital medication is invaluable, and I cannot express enough gratitude to The Max Foundation, [the pharmaceutical company], and my treating physicians for facilitating access to this treatment.”
– Serali, a farmer, father, and grandfather from Nepal living with chronic myeloid leukemia
Latest Developments
Am I Doing Enough?
By Pat Garcia-Gonzalez Birthdays are a time to take stock on our life. This birthday, I feel unsettled, questioning if I am doing everything I can. A few weeks ago, I sat in a small consult room. A gentleman walked wearing gray slacks, a white buttoned shirt, and suit coat, he must have been in….
First Doses of CLL treatment provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
Armenia and Nepal are the first of 29 countries to receive CLL treatment SEATTLE & BASEL & BEIJING & CAMBRIDGE, Mass. – March 13, 2024 — The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global oncology company, and….
The Max Foundation Announces Agreement with Lilly to Provide Access to Verzenio® (abemaciclib) for the Treatment of Advanced Breast Cancer in Kenya
Agreement to provide Verzenio® (abemaciclib) free of charge to patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) Lilly joins ongoing effort of Humanitarian Partnership for Access to Critical Treatment (Humanitarian PACT) to eliminate healthcare disparities for patients living with advanced breast cancer in low- and middle-income countries….
Overcoming Barriers to Access
Improving health outcomes for people living with cancer is about more than medication. We provide access to psychosocial support, transportation assistance, adherence monitoring, and more to ensure patient needs are handled individually and holistically.
Learn More
2023 M&E Report
Download Report